← Back to Search

Retinoid

Low-Dose Acitretin for Psoriasis

Phase 4
Waitlist Available
Research Sponsored by Frankel, Amylynne, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men must agree to use 2 forms of birth control (e.g. condoms, spermicide)
Adherence to alcohol avoidance during acitretin therapy and for 2 months after discontinuation of acitretin
Must not have
Guttate, erythrodermic, or pustular psoriasis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

This trial is looking at whether a lower dose of acitretin, a drug used to treat psoriasis, is as effective as the standard dose, but causes fewer side effects.

Who is the study for?
Adults with severe plaque-type psoriasis already taking 25mg/day of Acitretin and experiencing side effects may qualify. They must be on a stable phototherapy regimen, not use certain medications or have specific health conditions, avoid alcohol, agree to birth control measures, and commit to the study's duration without donating blood.
What is being tested?
The trial is testing if a lower dose of Acitretin (17.5 mg/day) can maintain effectiveness in treating severe plaque-type psoriasis while reducing side effects compared to the standard 25 mg/day dosage.
What are the potential side effects?
Potential side effects include hair loss, dryness in mouth/nose/eyes/skin, itching, sensitivity to light, liver issues, changes in blood fats and cholesterol levels, joint and muscle pain, eye problems like irritation or inflammation (conjunctivitis), headaches, nausea.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I agree to use two forms of birth control.
Select...
I will not drink alcohol while on acitretin and for 2 months after stopping it.
Select...
I am a woman who cannot become pregnant due to surgery or menopause.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My psoriasis is guttate, erythrodermic, or pustular.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Improvement in psoriasis
Secondary study objectives
Subjective efficacy/tolerability

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Low dose Acitretin (17.5 mg)Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Stiefel, a GSK CompanyIndustry Sponsor
60 Previous Clinical Trials
12,739 Total Patients Enrolled
11 Trials studying Psoriasis
1,457 Patients Enrolled for Psoriasis
Frankel, Amylynne, M.D.Lead Sponsor
2 Previous Clinical Trials
50 Total Patients Enrolled

Media Library

Acitretin (Retinoid) Clinical Trial Eligibility Overview. Trial Name: NCT01228409 — Phase 4
Psoriasis Research Study Groups: Low dose Acitretin (17.5 mg)
Psoriasis Clinical Trial 2023: Acitretin Highlights & Side Effects. Trial Name: NCT01228409 — Phase 4
Acitretin (Retinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01228409 — Phase 4
~1 spots leftby Dec 2025